Advanced Search

Acamprosate: Pharmacoeconomic Implications of Therapy

Contents:

Author Info

  • Rachel H. Foster

    (Adis International, Auckland, New Zealand)

  • Karen J. McClellan

    (Adis International, Auckland, New Zealand)

Registered author(s):

    Abstract

    _ Acamprosate is thought to reduce the craving for alcohol. The drug helps to maintain abstinence in alcohol-dependent patients who have successfully undergone detoxification. Abstinence rates during 3 to 12 months' treatment with acamprosate were approximately double those with placebo in most clinical trials, although abstinence rates were generally still <50% in patients assigned to receive acamprosate. _ The drug is generally well tolerated, with the most common adverse effect being diarrhoea. _ In a German cost-effectiveness model, a treatment programme including acamprosate was the dominant strategy, producing a lifetime cost saving of 2602 Deutschmarks (1992 to 1995 values) per additional abstinent patient compared with treatment without acamprosate. _ In a Belgian pharmacoeconomic model, total direct medical costs over 2 years were 21 301 Belgian francs (1997 values) per patient lower with a treatment programme including acamprosate than treatment without acamprosate in alcohol-dependent patients. _ The main factors in the cost savings with acamprosate in these models were reduced costs for acute hospitalisation and rehabilitation/follow-up. _ The results of a cost-benefit analysis that considered both direct and indirect costs for the total alcohol-dependent population in Spain were consistently in favour of acamprosate. The lifetime net benefit for acamprosate over placebo (the incremental benefit) ranged between 61 642 million and 99 069 million pesetas (1996 values) in various scenarios with 40 to 60% of patients receiving treatment.

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/pdfhandler.00019053-199916060-00010.pdf
    Download Restriction: Pay per view
    File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/fulltext.00019053-199916060-00010.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Springer Healthcare | Adis in its journal PharmacoEconomics.

    Volume (Year): 16 (1999)
    Issue (Month): 6 ()
    Pages: 743-755
    Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
    Handle: RePEc:wkh:phecon:v:16:y:1999:i:6:p:743-755

    Contact details of provider:
    Web page: http://pharmacoeconomics.adisonline.com/

    For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).

    Related research

    Keywords: Pharmacoeconomics; Reviews-on-treatment; Acamprosate; Alcoholism; Cost-effectiveness; Cost-analysis; Cost-benefit;

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:phecon:v:16:y:1999:i:6:p:743-755

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.